Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shire Pharmaceuticals Group PLC

http://www.shire.com

Latest From Shire Pharmaceuticals Group PLC

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

Scrip Asks Advanced Therapies

Finance Watch: Alto, Fractyl Bring IPO Count To Four, So Far, In 2024

Public Company Edition: Alto Neuroscience and Fractyl Health grossed $128.6m and $110m, respectively, while FibroBiologics went public in a direct listing. Also, Vaxcyte grossed $862.5m in a follow-on offering, Immunocore grossed $350m in a note sale and Vera raised $287.5m.

Financing Business Strategies

J.P. Morgan Day One: Novartis Reveals Two Deals, Pfizer's Bad Year, Bristol's Wobbly Growth

Daily notebook from the J.P. Morgan Healthcare Conference: Deal and strategy news from Novartis, BMS and Pfizer; Gilead talks lenacapavir PrEP launch plans; BioMarin's new CEO makes an appearance and Saunders explains the status at Bausch + Lomb.

Deals Strategy

IPOs Fizzle Out In The Fourth Quarter

Just three biotech companies floated in the last three months of 2023, but there may be hope for a resurgence next year.

Financing Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Advanced BioHealing, Inc. (renamed Shire Regenerative Medicine)
    • AesRX LLC
    • Baxalta Incorporated
    • BIKAM Pharmaceuticals Inc.
    • Chatham Therapeutics
    • Dyax Corp.
    • FerroKin BioSciences, Inc.
    • Fibrotech Therapeutics
    • Foresight Biotherapeutics Inc.
    • Gambro AB
    • Immuno-US
    • Jerini AG
    • Lotus Tissue Repair
    • Lumena Pharmaceuticals
    • Meritage Pharma, Inc.
    • Movetis NV
    • New Pervasis Therapeutics, Inc.
    • NPS Pharmaceuticals, Inc.
    • Premacure AB
    • Prism Pharmaceuticals, Inc.
    • River Pharmaceuticals
    • Roberts Pharmaceutical Corporation
    • SARcode Corporation
    • SuppreMol GmbH
    • Synovis Life Technologies, Inc.
    • Transkaryotic Therapies, Inc.
    • ViroPharma Inc.
UsernamePublicRestriction

Register